Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Atopic DermatitisSleep Disturbance

Interventions

DRUG

Dupilumab

12 week dupilumab administration

Trial Locations (1)

RECRUITING

Lurie Children's Hospital/Northwestern University, Chicago

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Northwestern University

OTHER